Mount Carmel Health Partners HEDIS Tip Sheets | Page 3

Table
Table of
of Contents
Contents
Annual Monitoring for Patients on Persistent Medications:
Angiotensin
Converting
Enzyme
Inhibitors
and Angiotensin
Receptor
Blockers (ARBs)............................... 4
Annual
Monitoring
for (ACE)
Patients
on Persistent
Medications:
Angiotensin
Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARBs) . . . . . . 3
Annual Monitoring for Patients on Persistent Medications: Digoxin...................................................................... 6
Annual Monitoring
for on
Patients
on Persistent
Medications:
Digoxin . . . . . . . . . . . . . . . . 4
Annual Monitoring
for Patients
Persistent
Medications:
Diuretics...................................................................
7
Monitoring for Patients on Persistent Medications: Diuretics . . . . . . . . . . . . . . . 5
Body Mass Annual
Index....................................................................................................................................................
9
Breast Cancer
......................................................................................................................................
11
Body Screening.
Mass Index
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Cervical Cancer
12
Breast Screening....................................................................................................................................
Cancer Screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Chlamydia Screening in Women........................................................................................................................... 13
Cervical Cancer Screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Colorectal Cancer Screening................................................................................................................................. 14
Chlamydia Screening in Women . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Controlling Blood Pressure................................................................................................................................... 16
Colorectal Cancer Screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Diabetes – Dilated Eye Exam................................................................................................................................ 17
Controlling Blood Pressure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Diabetes – HbA1c Control.................................................................................................................................... 19
Diabetes – Dilated Eye Exam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Diabetes – Medical Attention for Nephropathy................................................................................................... 20
– HbA1c Control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Diabetes – Diabetes
Statin Therapy....................................................................................................................................
22
Diabetes Anti‐Rheumatic
– Medical Attention
Nephropathy
. . . Arthritis............................................................
. . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Disease Modifying
Drug for
(DMARD)
Therapy . . for
23
Medication
Reconciliation
Discharge.
25
Diabetes
– Statin Post
Therapy
. . . . . . ..........................................................................................................
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Medication
Adherence
for Cholesterol................................................................................................................
26
Disease
Modifying
Anti-Rheumatic Drug (DMARD) Therapy for Arthritis . . . . . . . . . . . . . 17
Medication Adherence for Diabetes.................................................................................................................... 27
Medication Reconciliation Post Discharge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Medication Adherence for Hypertension............................................................................................................. 28
Medication Adherence for Cholesterol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Osteoporosis Management in Women Who Have Had a Fracture....................................................................... 30
Medication Adherence for Diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Transitions of Care (TRC)...................................................................................................................................... 32
Medication Adherence for Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Osteoporosis Management in Women Who Have Had a Fracture . . . . . . . . . . . . . . . . . . . 23
Transitions of Care (TRC) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3
24